A Phase 3 interventional study of Aliskiren and Amlodipine in Hypertension, sponsored by Novartis. Completed at 12 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-09.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.
Among the 89 studies testing aliskiren in Hypertension, this one is the 7th largest by enrollment, is one of 12 that started in 2008, is one of 38 in phase 3, and was the 49th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →
aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 39 · Phase 4 34
First in 2001; this study’s year is marked. 12 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,191 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 89 interventional studies. Of the 79 that completed or were terminated, 36 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 89 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 21st largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2008, is one of 108 in phase 3, and was the 145th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 89 studies testing aliskiren in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
msDBP and msSBP requirements:
3A:
3B:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
Drug: Aliskiren · Drug: Amlodipine · Drug: Placebo
Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
Drug: Aliskiren · Drug: Hydrochlorothiazide (HCTZ) · Drug: Placebo
Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
Drug: Amlodipine · Drug: Hydrochlorothiazide (HCTZ) · Drug: Placebo
Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
Drug: Aliskiren · Drug: Amlodipine · Drug: Hydrochlorothiazide (HCTZ) · Drug: Placebo
150 and 300 mg tablets
5 and 10 mg capsules
12.5 and 25 mg capsules
tablet
capsules
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
Time frame: Baseline to end of study (Week 8)
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)
Blood pressure control was defined as a msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.
Time frame: End of study (Week 8)
Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)
Twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed in a subset of patients twice during the study, once at baseline and again at Week 8. The ABPM device was placed on the non-dominant arm between 7:00 and 10:00 am and verification readings obtained. If they were successful, the investigator initiated the 24 hour reading and instructed the patient regarding ABPM procedures. On the next day, the ABPM device was removed if it had been worn for a minimum of 24 hours. The ABPM data were downloaded and evaluated on site.
Time frame: Baseline to end of study (Week 8)
| Milestone | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide |
|---|---|---|---|---|
| Started | 287 | 298 | 296 | 310 |
| Completed | 266 | 276 | 279 | 285 |
| Not completed | 21 | 22 | 17 | 25 |
| Withdrew: Adverse event | 7 | 2 | 8 | 11 |
| Withdrew: Abnormal laboratory value(s) | 0 | 0 | 1 | 0 |
| Withdrew: Abnormal test procedure result(s) | 1 | 3 | 1 | 2 |
| Withdrew: Lack of efficacy | 2 | 3 | 1 | 2 |
| Withdrew: Protocol violation | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 7 | 3 | 8 |
| Withdrew: Lost to follow-up | 4 | 6 | 2 | 1 |
| Withdrew: Randomized in error - no study drug | 0 | 1 | 0 | 1 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
| mmHg | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide |
|---|---|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) | -31.37 ± 0.90 | -27.99 ± 0.88 | -30.77 ± 0.88 | -37.92 ± 0.86 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
| mmHg | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide |
|---|---|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) | -18.03 ± 0.57 | -14.32 ± 0.55 | -17.03 ± 0.55 | -20.63 ± 0.54 |
Blood pressure control was defined as a msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.
| Percentage of patients | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide |
|---|---|---|---|---|
| Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8) | 41.3 | 33.1 | 39.0 | 62.3 |
Twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed in a subset of patients twice during the study, once at baseline and again at Week 8. The ABPM device was placed on the non-dominant arm between 7:00 and 10:00 am and verification readings obtained. If they were successful, the investigator initiated the 24 hour reading and instructed the patient regarding ABPM procedures. On the next day, the ABPM device was removed if it had been worn for a minimum of 24 hours. The ABPM data were downloaded and evaluated on site.
| mmHg | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide |
|---|---|---|---|---|
| Systolic BP | -20.30 ± 0.52 | -16.27 ± 0.51 | -18.67 ± 0.53 | -25.29 ± 0.51 |
| Diastolic BP | -13.29 ± 0.36 | -9.57 ± 0.35 | -11.20 ± 0.37 | -15.90 ± 0.35 |
Collected over During the 8 week double blind treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aliskiren / Amlodipine | — | 3/287 (1%) | 32/287 (11.1%) |
| Aliskiren / Hydrochlorothiazide | — | 2/297 (0.7%) | 17/297 (5.7%) |
| Amlodipine / Hydrochlorothiazide | — | 2/295 (0.7%) | 26/295 (8.8%) |
| Aliskiren / Amlodipine / Hydrochlorothiazide | — | 6/309 (1.9%) | 29/309 (9.4%) |
| Event | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide |
|---|---|---|---|---|
| Hepatitis AInfections and infestations | 1/287 | 0/297 | 0/295 | 0/309 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/287 | 0/297 | 0/295 | 0/309 |
| Nasal septum deviationRespiratory, thoracic and mediastinal disorders | 1/287 | 0/297 | 0/295 | 0/309 |
| Cerebrovascular accidentNervous system disorders | 0/287 | 0/297 | 1/295 | 0/309 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/287 | 0/297 | 1/295 | 0/309 |
| Tubo-ovarian abscessInfections and infestations | 0/287 | 1/297 | 0/295 | 0/309 |
| Stress urinary incontinenceRenal and urinary disorders | 0/287 | 1/297 | 0/295 | 0/309 |
| Acute coronary syndromeCardiac disorders | 0/287 | 0/297 | 0/295 | 1/309 |
| Arrhythmia supraventricularCardiac disorders | 0/287 | 0/297 | 0/295 | 1/309 |
| GoitreEndocrine disorders | 0/287 | 0/297 | 0/295 | 1/309 |
| Event | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide |
|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 23/287 | 6/297 | 12/295 | 22/309 |
| HeadacheNervous system disorders | 9/287 | 12/297 | 15/295 | 11/309 |
| Age Continuous(years) | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide | Total |
|---|---|---|---|---|---|
| Mean | 54.4 ± 11.33 | 55.5 ± 10.75 | 55.1 ± 10.86 | 55.4 ± 10.54 | 55.1 ± 10.86 |
| Age, Customized(participants) | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide | Total |
|---|---|---|---|---|---|
| < 65 years | 237 | 242 | 233 | 251 | 963 |
| >=65 years | 50 | 56 | 63 | 59 | 228 |
| Sex: Female, Male(Participants) | Aliskiren / Amlodipine | Aliskiren / Hydrochlorothiazide | Amlodipine / Hydrochlorothiazide | Aliskiren / Amlodipine / Hydrochlorothiazide | Total |
|---|---|---|---|---|---|
| Female | 115 | 123 | 110 | 123 | 471 |
| Male | 172 | 175 | 186 | 187 | 720 |
The record gives a start of Sep 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aliskiren · Amlodipine · Hydrochlorothiazide